About this trial
Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact.
Coagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and/or progression of liver diseases is still not fully understood.
A better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.
Eligibility criteria
Qualifiers
Liver biopsy showing chronic liver disease or cirrhosis
Liver elastography by Fibroscan® assessing the elasticity of the liver at more than 10 kpa
Combination of clinical, biological and imaging criteria characteristic of chronic liver disease (signs of portal hypertension, liver failure and liver dysmorphia in a patient with at least one risk factor for chronic liver disease)
Disqualifiers
Pregnant or lactating women
Protected populations: persons under guardianship, under curatorship or safeguard of justice
Patient under AME
Patient who has not signed a consent form
Trial design
Treatments tested in this trial
- biomarker assay
Treatment groups
6
Treatment groupsSee each treatment group below.
Locations
1Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor